证券代码：002393 证券简称：力生制药 公告编号：2025-059 天津力生制药股份有限公司 关于药品氯化钾缓释片通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四、对本公司的影响及风险提示 公司该药品通过上市许可申请，将进一步丰富公司治疗消化系统疾病药物产品线， 提高公司市场竞争力。根据国家相关政策，公司产品氯化钾缓释片按化学药品3类批准 生产，可视同通过一致性评价，这将有利于扩大公司产品的市场销售，对公司的未来经 营业绩产生积极影响。由于医药产品的行业特点，各类产品/药品的具体销售情况可能 受到市场环境变化等因素影响，具有较大不确定性，敬请广大投资者注意投资风险。 特此公告。 天津力生制药股份有限公司 二、该药品的基本情况 | 药品名称 | | 氯化钾缓释片 | | | --- | --- | --- | --- | | 剂 | 型 | 片 剂 | | | 规 | 格 | 0.5g | 0.6g | | 注册分类 | | 化学药品 | | | 药品生产企业 | | 天津力生制药股份有限公司 | | | 原药品批准文号 | | 无 ...

Core Viewpoint - The company has received drug registration certificates for two specifications of potassium chloride sustained-release tablets, indicating successful approval for market entry [1] Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets in 0.5g specification [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets in 0.6g specification [1] - Both products have successfully passed the drug market licensing application [1]

证券日报网讯 8月25日晚间，力生制药发布公告称，公司将参加由天津证监局指导、天津上市公司协会 及深圳市全景网络有限公司联合举办的"2025年天津辖区上市公司投资者网上集体接待日活动"。 （编辑 姚尧） ...

证券代码：002393 证券简称：力生制药 公告编号：2025-058 天津力生制药股份有限公司 关于参加2025年天津辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津力生制药股份有限公司（以下简称"公司"）将 参加由天津证监局指导、天津上市公司协会及深圳市全景网络有限公司联合举办的"2025年 天津辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net）； 或关注微信公众号（名称：全景财经）；或下载全景路演APP，参与本次互动交流。活动时 间为2025年9月11日（周四）15:00-17:00。出席本次活动的有公司独立董事方建新先生、财 务总监王家颖先生和董事会秘书马霏霏女士，届时公司高管将在线就公司2025年半年度业 绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与。 特此公告。 天津力生制药股份有限公司 董事会 20 ...

Group 1 - The company achieved a revenue of 732 million yuan and a net profit attributable to shareholders of 343 million yuan in H1 2025, representing a year-on-year increase of 235.04% [1] - The significant growth in net profit is primarily due to cash dividends received from Tian Shili Bio, in which the company's wholly-owned subsidiary, Central Pharmaceutical, holds a 12.15% stake, amounting to 303.75 million yuan [1] - The company maintains a gross margin of 59.16% and a net profit margin of 14.25% in H1 2025, reflecting improvements of 3 percentage points and 0.93 percentage points year-on-year, respectively [1] Group 2 - The company has identified over 300 quality projects and is preparing to establish an industrial merger and acquisition fund [2] - In H1 2025, the company invested 60.51 million yuan in R&D, with an investment rate exceeding 8%, resulting in multiple breakthroughs and the approval of three core products [2] - The company has enhanced its marketing and production capabilities, with significant sales growth in various products, including a 14% increase in sales revenue for urokinase injection and a 48% surge in external sales of heparin sodium injection [2]

Core Insights - The company reported a revenue of 732 million yuan for the first half of 2025, a decrease of 1.76% year-on-year, while net profit increased by 235.04% to 343 million yuan [1] - The company focuses on the pharmaceutical health industry, with a product portfolio that includes 296 drugs across 15 categories, and has received 111 patent authorizations [1] - The company is implementing a dual-driven strategy of "industrial operation + capital operation" and is actively engaged in CMO/CDMO services to support the pharmaceutical innovation ecosystem in Tianjin [1] Financial Performance - Revenue for the first half of 2025 was 732 million yuan, down 1.76% from the previous year [1] - Net profit reached 343 million yuan, marking a significant increase of 235.04% year-on-year [1] - The company invested 60.51 million yuan in R&D, representing over 8% of its revenue [2] R&D and Innovation - The company made breakthroughs in R&D, applying for 9 patents and obtaining 2 during the reporting period [2] - It completed the application for 7 generic drugs and achieved approval for 3 core products, including Cefaclor sustained-release tablets and Voriconazole [2] Marketing and Sales Strategy - The company established a "four-wheel" marketing system, focusing on the core product Indapamide to enhance its distribution network in first and second-tier markets [2] - The company adopted a dual strategy of "academic promotion + brand building" to accelerate the market entry of 4 new generic drugs [2] - Retail segment revenue grew rapidly due to enhanced customer engagement through precise brand positioning [2] Business Development - The CMO/CDMO business achieved breakthroughs with the signing of 2 project contracts [3] - The company plans to establish a 1 billion yuan investment fund in collaboration with other financial entities, with an initial investment of 500 million yuan [3] - This investment is expected to optimize the company's business structure and enhance its operational strength [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved significant profit growth, with a 235.04% year-on-year increase in net profit attributable to shareholders, reaching 343 million yuan in H1 2025 [4] - The substantial profit increase is primarily due to cash dividends received from a subsidiary, Central Pharmaceutical, amounting to 303.75 million yuan [4] - The company is focusing on deep integration of innovation and industrial resources to drive high-quality development [4] - The projected net profits for 2025-2027 are estimated at 466 million yuan, 291 million yuan, and 331 million yuan respectively, with corresponding EPS of 1.81, 1.13, and 1.28 yuan per share [4] Financial Performance - In H1 2025, the company reported revenues of 732 million yuan and a gross margin of 59.16%, which is an increase of 3 percentage points year-on-year [4] - The net profit margin for H1 2025 was 14.25%, up by 0.93 percentage points year-on-year [4] - The company’s total market capitalization is 6.592 billion yuan, with a circulating market capitalization of 6.403 billion yuan [1] Research and Development - The company has identified over 300 quality projects and invested 60.51 million yuan in R&D in H1 2025, representing an investment rate of over 8% [5] - The company applied for 9 patents and received approval for 3 core products [5] Market Strategy - The company is enhancing its distribution network and product value chain, particularly focusing on its core product, Indapamide [5] - The company is also establishing a 1 billion yuan equity investment fund to strengthen its operational capabilities [4][5]

Core Viewpoint - Tianjin Development (00882) reported financial results for its indirect non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical (002393) for the six months ending June 30, 2025, showing a mixed performance with a decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the period was 732 million RMB, representing a year-on-year decrease of 1.76% [1] - Net profit attributable to the parent company was 343 million RMB, reflecting a substantial year-on-year increase of 235.04% [1] - Basic earnings per share stood at 1.33 RMB [1]

Group 1 - The company Tianjin Development (00882) reported its indirect non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical) financial results for the six months ending June 30, 2025, with total revenue of 732 million RMB, a year-on-year decrease of 1.76% [1] - The net profit attributable to the parent company was 343 million RMB, representing a significant year-on-year increase of 235.04% [1] - The basic earnings per share were reported at 1.33 RMB [1]

Group 1 - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Lifesun Pharmaceutical (002393), plans to establish a fund with several partners, including Jianxin Equity and Teda Private Equity, with a proposed total subscription amount of RMB 500 million [1] - Lifesun Pharmaceutical intends to contribute RMB 174 million to the fund, representing 34.75% of the total proposed subscription amount [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), is proposed to have a duration of five years and will primarily invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction, if realized, will help the group deepen its understanding of the latest industry developments in the pharmaceutical sector, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The board also considers that the investment in the fund could provide more industry acquisition opportunities aligned with the company's development strategy, offering potential returns beyond fixed income and improving capital allocation efficiency [1]